ObjectiveTo observe the clinical efficacy and safety of Modified Guomin Decoction （加味过敏煎， MGD） in patients with mild to moderate atopic dermatitis （AD） of the traditional Chinese medicine （TCM） pattern of heart fire and spleen deficiency， and to explore its possible mechanisms. MethodsIn this randomized， double-blind， placebo-controlled study， 72 patients with mild to moderate AD and the TCM pattern of heart fire and spleen deficiency were randomly divided into a treatment group and a control group， with 36 cases in each group. The treatment group received oral MGD granules combined with topical vitamin E emulsion， while the control group received oral placebo granules combined with topical vitamin E treatment. Both groups were treated twice daily for 4 weeks. Clinical efficacy， TCM syndrome scores， Visual Analogue Scale （VAS） for pruritus， Dermatology Life Quality Index （DLQI） scores， Scoring Atopic Dermatitis （SCORAD） and serum biomarkers， including interleukin-33 （IL-33）， interleukin-1β （IL-1β）， immunoglobulin E （IgE）， and tumor necrosis factor-α （TNF-α） were compared before and after treatment. Safety indexes was also assessed. ResultsThe total clinical effective rates were 77.78% （28/36） in the treatment group and 38.89% （14/36） in the control group， with cure rates of 19.44% （7/36） and 2.78% （1/36）， respectively. The treatment group showed significantly better clinical outcomes compared to the control group （P＜0.05）. The treatment group exhibited significant reductions in total TCM syndrome scores， including erythema， edema， papules， scaling， lichenification， pruritus， irritability， insomnia， abdominal distension， and fatigue scores， as well as reductions in VAS， DLQI， SCORAD， and serum IgE and IL-33 levels （P＜0.05 or P＜0.01）. Compared to the control group， the treatment group had significantly better improvements in all indicators except for insomnia （P＜0.05）. No adverse events occurred in either group. ConclusionMGD is effective and safe in treating mild to moderate AD patients with heart fire and spleen deficiency pattern. It significantly alleviates pruritus， improves TCM syndromes and quality of life， and enhances clinical efficacy， possibly through modulation of immune responses.

OBJECTIVE To investigate the risk factors for tigecycline -induced hypofibrinogenaemia by systematic review . METHODS The literature about risk factors for tigecycline -induced hypofibrinogenaemia were retrieved from English databases （PubMed，Cochrane Library ，Embase，Web of Science ）and Chinese databases （CNKI，Wanfang Database ，VIP，CBM）during the inception to Feb . 5th，2022. At the same time ，the unpublished clinical trial data were additionally searched . After the quality evaluation of the included literature was carried out by adopting the Castle -Ottawa Scale （NOS），data were extracted from the literature that met the inclusion criteria ，and Meta -analysis was conducted by using RevMan 5.3 software. RESULTS Finally，8 literature were selected ，with a total of 1 374 cases，including 706 cases in the trial group and 668 cases in the control group . There were 4 Chinese and 4 English literature ，all of which were case control studies published between 2017-2021. Meta-analysis showed that the risk factors for tigecycline -induced hypofibrinogenaemia were age [OR＝1.04，95%CI（1.02，1.06），P＝0.000 5]，baseline fibrinogen level [OR＝0.54，95%CI（0.42，0.69），P＜0.000 01]，abdominal infection （sensitivity analysis ）[OR＝9.43，95%CI（4.24， 20.95），P＜0.000 01]，dose each time [OR＝2.87，95%CI（2.04，4.02），P＜0.000 01]，medication time [OR＝1.10，95%CI（1.00， 1.22），P＝0.04]. CONCLUSIONS Advanced age ，low baseline fibrinogen levels ，abdominal cavity infection ，relative high dose each time and slightly long medication time are potential risk factors for tigecycline -induced hypofibrinogenaemia . If the above risk factors exist ，it is suggested to pay close attention to the occurrence of hypofibrinogenaemia in the course of tigecycline administration.

OBJECTIVE To analyze the influential factors for dose-corrected trough concentration （C/D） of amisulpride， and to provide reference for rational use of it in clinic. METHODS The results of the last serum concentration monitoring and relevant medical data of schizophrenic inpatients who were monitored for the treatment of amisulpride in the Mental Health Center of the First Hospital of Hebei Medical University from March to November 2021 were collected retrospectively and analyzed the effects of age， sex， body mass index （BMI）， serum creatinine level， and combined medication on the C/D value of amisulpride. RESULTS A total of 133 schizophrenic inpatients were included， and median dose of amisulpride was 600.00 mg/d， median serum concentration was 332.57 ng/mL， and median value of C/D was 0.61 ng·d/（mL·mg）. The serum concentration of 49 patients was within the recommended range of relevant guideline （100-320 ng/mL）， and 27 patients exceeded the laboratory warning concentration （640 ng/mL）. There was no statistical significance in drug dose， serum concentration or C/D value among the patients of different genders （P＞0.05）. The serum concentration of minor patients was significantly lower than that of adult patients （P＜0.05）， but there was no statistical significance in drug dose or C/D value between minor patients and adult patients （P＞0.05）. The C/D value of amisulpride in obese patients （BMI＞28 kg/m2） was significantly lower than that in normal patients （BMI 18.5- 23.9 kg/m2）； the combination of olanzapine， sodium valproate and benzodiazepines did not affect the C/D value of amisulpride （P＞0.05）； the level of serum creatinine in patients was not related to the dose of amisulpride （r＝0.081， P＞0.05）， but was positively related to the C/D value of the drug （r＝0.285， P＜0.05）. CONCLUSIONS The age， BMI and serum creatinine level of patients are closely related to the C/D value of amisulpride. In the clinical treatment of schizophrenia with amisulpride， we should fully consider the patient’s age， body mass， serum creatinine and other factors， and develop a personalized drug regimen for patients to ensure the safety and effectiveness of treatment.

Objective In order to know the baseline data of water iodine and the iodine nutritional status of 8-10 years old children in Chaoyang District of Beijing,to evaluate the current status of iodine deficiency disorders so as to provide a basis for taking targeted preventive measure and adjusting the intervention strategies scientifically.Methods Multi-stages sampling method was used to select drinking water samples from 43 subdistricts or townships in Chaoyang,and the water iodine content in the drinking water was determined.A cluster sampling method was applied to select 8-10 years old children from primary schools in 5 subdistricts or townships,and the iodine contents of urine and salt were determined.And B ultrasonic examination was carried out for diagnosis of thyroid disease.Results The median iodine content of drinking water in Chaoyang was 4.85 μg/L,the iodine content of self-provided wells (5.65 μg/L) was higher than that of municipal water (3.80 μg/L,Z =-3.469,P ＜ 0.05).The coverage rate of iodized salt was 88.06％ (177/201) and the qualified rate of iodized salt was 81.59％ (164/ 201).The median urinary iodine was 165.00 μ g/L,median urinary iodine in boys (174.00 μg/L) was higher than that of girls (146.00 μg/L Z =-2.434,P ＜ 0.05).The goiter rate diagnosed by B ultrasound was 1.49％ (3/201),the thyroid nodule rate was 24.88％ (50/201).Conclusions The iodine content of drinking water in the Chaoyang District is low,and it is still in the external environment of iodine deficiency (＜ 10 μg/L).The 8-10 years old children of Chaoyang show a good iodine nutritional status,however,neither the coverage rate nor the qualified rate of iodized salt has reached the standard of elimination of iodine deficiency disorders,and scientific iodine can not be ignored.

OBJECTIVE： To optimize the water extraction technology of Chaihu anxin capsules. METHODS： Taking comprehensive scoring value of  the contents of gallic acid，chlorogenic acid，puerarin，glycoside，rutin，cinnamic acid， quercetin and the yield of extract as investigation index， using multiple of adding liquid， soaking time， reflux time and extraction times as factors， water extraction technology of Chaihu anxin capsule was optimized by Box-Behnken response surface method based on single factor test. Validation test was conducted. RESULTS： The optimal extraction technology of Chaihu anxin capsules was adding 11 times of water， soaking for 10 h， extracting for 2 times， refluxing for 1.5 h each time. In validation test， the relative deviation of comprehensive scoring value to predicted value was 1.87％ for 3 batches of samples （RSD＜2％， n＝3）. CONCLUSIONS： The optimal extraction technology is simple， stable and suitable for further production of Chaihu anxin capsules.

OBJECTIVE： To evaluate the effects of clinical pharmacist-led ischemic stroke management， and to provide reference for chronic disease management. METHODS： Totally 184 patients with ischemic stroke who were hospitalized in neurology department of the First Hospital of Hebei Medical University from May to August 2018 were included prospectively， and then divided into control group （92 cases） and intervention group （92 cases） by random number method. Control group did not receive clinical pharmacist intervention. In the intervention group， clinical pharmacists were the leader in the pharmaceutical care during the hospitalization， the medication education at discharge， and pharmacy follow-up after discharge. The rate of medication compliance （antiplatelet drugs， antihypertensive drugs， hypoglycemic drugs and lipid-lowering drugs） and the rate of secondary prevention and control indicators of ischemic stroke， such as blood pressure， blood glucose [glycated hemoglobin （HbA1c）] and blood lipid [low-density lipoprotein cholesterol （LDL-C）] were investigated between 2 groups at 6 months after discharge. The incidence of adverse drug reaction and the rate of rehospitalization were compared between 2 groups at 6 months after discharge. RESULTS： The number of patients in the intervention group and the control group was 84 and 82， respectively. At 6 months after discharge， the compliance rate of antiplatelet drugs in the intervention group was 96.43％， which was higher than 95.13％ of control group， but the difference was not statistically significant. The good compliance rates of antihypertensive drugs， hypoglycemic drugs and lipid-lowering drugs in the intervention group were 92.86％， 91.67％ and 77.38％， which were higher than 78.57％， 69.70％ and 60.98％ of control group， with statistical significance （P＜0.05）. The qualified rate of index of blood pressure was 89.29％ in intervention group， which was higher than 76.79％ of control group， but the difference was not statistically significant. The qualified rates of HbA1c and LDL-C in the intervention group were 80.56％ and 66.67％， which were higher than 57.58％ and 48.785 of control group， with statistical significance （P＜0.05）. The incidence of total adverse drug reactions in the intervention group was 15.48％， which was lower than 20.73％ of control group， but the difference was not statistically significant. The total rehospitalization rate in the intervention group was 7.14％， which was lower than 17.86％ of control group， the difference was statistically significant （P＜0.05）. CONCLUSIONS： The management of ischemic stroke patients with clinical pharmacists as the leading factor can improve the patient’s medication compliance， improve the qualified rate of secondary prevention and control indicators of ischemic stroke， and reduce the rate of rehospitalization.

OBJECTIVE： To optimize the ultrasonic extraction technology for Jinjuan shengban capsules. METHODS： Using comprehensive score of indexes as transfer rate of gallic acid， chlorogenic acid， baicalin， aloe emodin and emodin methyl ether， with ethanol volume fraction， ultrasonic power， ultrasonic extraction time and liquid-material ratio as factors， the ultrasound extraction technology of Jinjuan shengban capsules was optimized by Box-Behnken response surface methodology based on single factor test. The validation test was conducted. RESULTS： The best extraction technology was 50-fold 70％ ethanol， extracting 40 min under 300 W. In validation test， average transfer rates of gallic acid， chlorogenic acid， baicalin， aloe emodin and emodin methyl ether were 85.92％， 86.37％， 92.76％， 90.84％ and 87.26％ （RSD＜3.57％，n＝3） in 3 batches of samples； comprehensive score was 88.95％， relative error of which to predicted value of 88.27％ was 1.10％. CONCLUSIONS： The response surface method combined with multi-index comprehensive scoring can be used to optimize the extraction technology of Jinjuan shengban capsules which is simple and stable.

Objective:To investigate the effect of anastrozole on sex hormone levels and michigan cancer foundation-7 ( MCF-7 ) cell inhibition in postmenopausal women with breast cancer. Methods: Totally 80 women with breast cancer were selected. Among them, 40 cases of patients received the routine management and tamoxifen treatment were included into the control group, and another 40 cases of patients received the routine management and anastrozole treatment were included into the observation group. The changes of sex hormone levels, effects and adverse drug reactions of two groups were compared between basetine and three months after treat-ment, meanwhile, the incidence of MCF-7 cell inhibition between two groups. Results:After treatment, the levels of estradiol( ER) , progesterone(PR) and luteotropic hormone(LH) were lower than baselime, however, the level of testosterone was contrary(P <0. 05). Meanwhile, the level of ER, PR and LH in control group were lower than baselime however, the level of testosterone was cont-ray (P<0. 05). The incidence of MCF-7 cell inhibillion between two grugs at time 72 h were higher than the 48 h, the incedence of MCF-7 cell inhibition in observation group were significantly higher than control groups at time 48 h and 72 h (P<0. 05). The rate of total effective in control group(45. 0%) was lower than the observation group(70. 0%)(P>0. 05). There was no significant differente in the micidence of adverse reactions. Conclusion:Anastrozole used for postmenopausal women with breast cancer has significant effi-cacy, high safety and promising inhibitory effect on MCF-7 cell. It can effectively adjust sex hormone level, reduce occurrence and transfer risks of breast cancer.

Objective:To investigate the effect of anastrozole on sex hormone levels and michigan cancer foundation-7 ( MCF-7 ) cell inhibition in postmenopausal women with breast cancer. Methods: Totally 80 women with breast cancer were selected. Among them, 40 cases of patients received the routine management and tamoxifen treatment were included into the control group, and another 40 cases of patients received the routine management and anastrozole treatment were included into the observation group. The changes of sex hormone levels, effects and adverse drug reactions of two groups were compared between basetine and three months after treat-ment, meanwhile, the incidence of MCF-7 cell inhibition between two groups. Results:After treatment, the levels of estradiol( ER) , progesterone(PR) and luteotropic hormone(LH) were lower than baselime, however, the level of testosterone was contrary(P <0. 05). Meanwhile, the level of ER, PR and LH in control group were lower than baselime however, the level of testosterone was cont-ray (P<0. 05). The incidence of MCF-7 cell inhibillion between two grugs at time 72 h were higher than the 48 h, the incedence of MCF-7 cell inhibition in observation group were significantly higher than control groups at time 48 h and 72 h (P<0. 05). The rate of total effective in control group(45. 0%) was lower than the observation group(70. 0%)(P>0. 05). There was no significant differente in the micidence of adverse reactions. Conclusion:Anastrozole used for postmenopausal women with breast cancer has significant effi-cacy, high safety and promising inhibitory effect on MCF-7 cell. It can effectively adjust sex hormone level, reduce occurrence and transfer risks of breast cancer.

Objective The aim of this study was to investigate the effects of the ERK5 pathway on bone morphogenetic protein?9(BMP9)?regu?lated osteogenic/odontogenic differentiation of immortalized stern cells from the apical papilla(iSCAP). Methods BMP9 was introduced into the iSCAP by using recombinant adenoviruses,and the P?ERK5 protein expression was measured via western blotting. Then,the osteogenic/odontoblas?tic changes were analyzed by alkaline phosphatase(ALP)staining and Alizarin red staining,and the expression of osteogenic/odontoblast?associat?ed genes,such as Runx2,OCN,OPN,and DMP1 was measured by RT?PCR. Results BMP9 could up?regulate the phosphorylation of ERK5 in iSCAP. After using BIX02189,which was an inhibitor of ERK5,the phosphorylation of ERK5;the activity of ALP;the expression of Runx2, OCN,OPN,and DMP1;and the calcium deposition were all significantly inhibited. Conclusion The ERK5 signaling pathway plays an important role in BMP9?regulated osteogenic/odontogenic differentiation of iSCAP.